Birincil kaynak kaydı
GSK, tebipenem HBr için FDA'ya NDA yeniden sunumunu dosyaladı. Dosyalama, Spero'ya 25 milyon dolarlık bir kilometre taşı ödemesini tetikliyor ve 2026 1. Çeyrek'te bekleniyor. NDA, piyelonefrit dahil karmaşık idrar yolu enfeksiyonlarının tedavisini kapsıyor.
8-K NASDAQ false 0001701108 0001701108 2025-12-19 2025-12-19 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2025 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 675 Massachusetts Avenue , 14 th Floor Cambridge , Massachusetts 02139 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code (857) 242-1600 Check the appropriate box below if the Form 8-K filing is intended to simultaneo